Company Info

Allergan, plc

Drug Discovery & Development

Overview

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Contributions

Contributors

Contributions

15 Contributions1 / 1

FDA Approval

Allergan Receives FDA Approval for Migraine Treatment

Allergan, plc

PR-M01-20-NI-001Jan 02, 2020

Collaboration

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Allergan, plc

PR-M11-19-NI-013-1960Nov 14, 2019

FDA Approval

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Allergan, plc

PR-M03-19-NI-054Mar 20, 2019

Data

Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.

Allergan, plc

PR-M03-19-NI-004Mar 01, 2019

Response

Allergan Responds to Public Shareholder Letter

Allergan, plc

PR-M02-19-NI-047Feb 21, 2019

Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

Allergan, plc

PR-M10-18-NI-024Oct 08, 2018

Appointment

Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

Allergan, plc

PR-M08-18-NI-096Aug 22, 2018

Collaboration

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan, plc

PR-M08-18-NI-062Aug 17, 2018

Fast Track

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

Allergan, plc

PR-M07-18-NI-080Jul 24, 2018

Clinical Data

Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant

Allergan, plc

PR-M06-18-NI-051Jun 14, 2018

Drug Delivery

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting

Allergan, plc

PR-M04-18-NI-55Apr 17, 2018

Results

Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression

Allergan, plc

PR-M04-18-NI-018Apr 05, 2018

Earnings

Allergan to Report First Quarter 2018 Earnings and Host Conference Call and Webcast

Allergan, plc

PR-M04-18-NI-012Apr 04, 2018

NDA

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Allergan, plc

PR-M02-18-NI-108Feb 28, 2018

FDA Approval

FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia

Allergan, plc

PR-M02-18-NI-029Feb 08, 2018

1 / 1

0 Contributors1 / 0

No authors found

1 / 0